Emphysema

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

NCT00670007 | PHASE 4 | INTERVENTIONAL

This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® intravenous (i.v). administration in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The long-term verification of a disease-modifying benefit of Zemaira® on the progression of emphysema will be assessed by volume-adjusted lung density, measured yearly by computed tomography (CT).

21 Sites

140 Participants

Recruiting

18 Years to 84 Months

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

Adelaide,South Australia,Australia,5000

Study Site

Fitzroy,Victoria,Australia,3065

Study Site

Darlinghurst,Australia,2010

Study Site

Nedlands,Australia,6009

Study Site

New Lambton,Australia,2305

Study Site

Vancouver,British Columbia,Canada,V6J1S3

Study Site

Halifax,Nova Scotia,Canada,B3H3A7

Study Site

Toronto,Ontario,Canada,M5T2S8

Study Site

Praha 4 - Krc,Czech Republic,14059

Study Site

Arhus C,Denmark,8000

Study Site

Hellerup,Denmark,2900

Study Site

Tartu,Estonia,51014

Study Site

Oulu,Finland,90220

Study Site

Essen,Germany,45239

Study Site

Heidelberg,Germany,69126

Study Site

Nürnberg,Germany,90419

Study Site

Dublin,Ireland,9

Study Site

Krakow,Poland,31-066

Study Site

Warsaw,Poland,01-138

Study Site

Bucuresti,Romania,011026

Study Site

Malmo,Sweden,20502

Study Eligibility Criteria

Inclusion Criteria

* Subjects who have completed the 2-year treatment and observation period in the Phase 3/4 Zemaira® CE1226_4001 study (NCT00261833) and are willing to sign informed consent
* Males, and non-pregnant, non-lactating females, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator

Exclusion Criteria

* Individuals residing in the US
* Current evidence of alcohol abuse or abuse of drugs such as barbiturates, benzodiazepines, amphetamines, cocaine, opioids, and cannabinoids
* History of allergy, anaphylactic reaction, or severe systemic response to human plasma derived products, or known mannitol hypersensitivity, or history of prior adverse reaction to mannitol
* Current tobacco smoker (smoking must be discontinued for at least 6 months prior to study participation)
* Conditions or behaviors that interfere with attending scheduled study visits in the opinion of the investigator
* History of non-compliance
* Administration of any other experimental new drug or participation in an investigation of a marketed product
* Inability to perform necessary study procedures

Additional Studies

Additional studies can be found at ClinicalTrials.gov